{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:08:40Z","timestamp":1775844520529,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007289","name":"Nanjing Medical University","doi-asserted-by":"publisher","award":["JX218GSP20211804A"],"award-info":[{"award-number":["JX218GSP20211804A"]}],"id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["LK2021002"],"award-info":[{"award-number":["LK2021002"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["BJ20015"],"award-info":[{"award-number":["BJ20015"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20201490"],"award-info":[{"award-number":["BK20201490"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071434"],"award-info":[{"award-number":["82071434"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016334","name":"Jiangsu Province Hospital","doi-asserted-by":"publisher","award":["JSPH-MA-2023-5"],"award-info":[{"award-number":["JSPH-MA-2023-5"]}],"id":[{"id":"10.13039\/501100016334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016334","name":"Jiangsu Province Hospital","doi-asserted-by":"publisher","award":["JSPH-MC-2021-7"],"award-info":[{"award-number":["JSPH-MC-2021-7"]}],"id":[{"id":"10.13039\/501100016334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.clineuro.2024.108462","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T21:58:14Z","timestamp":1721339894000},"page":"108462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cytokines in cerebrospinal fluid as a prognostic predictor after treatment of nusinersen in SMA patients"],"prefix":"10.1016","volume":"244","author":[{"given":"Xi","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Bei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-Hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2024.108462_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.clineuro.2024.108462_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"Oskoui","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2024.108462_bib3","article-title":"Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study","author":"Bitetti","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.clineuro.2024.108462_bib4","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2024.108462_bib5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/brain\/awac252","article-title":"Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy","volume":"146","author":"Pechmann","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.clineuro.2024.108462_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5582\/irdr.2022.01094","article-title":"Assessment of health-related quality of life in patients with spina muscular atrophy in China","volume":"11","author":"Duan","year":"2022","journal-title":"Intractable Rare Dis. Res"},{"key":"10.1016\/j.clineuro.2024.108462_bib7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","article-title":"Spinal muscular atrophy - insights and challenges in the treatment era","volume":"16","author":"Mercuri","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.clineuro.2024.108462_bib8","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1111\/ene.14902","article-title":"Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen","volume":"28","author":"Meyer","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clineuro.2024.108462_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejpn.2022.12.003","article-title":"Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment","volume":"42","author":"Scheijmans","year":"2023","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.clineuro.2024.108462_bib10","first-page":"4061","article-title":"A severe mouse model of spinal muscular atrophy develops early systemic inflammation","volume":"27","author":"Wan","year":"2018","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.clineuro.2024.108462_bib11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jphs.2020.09.001","article-title":"Survival motor neuron protein regulates oxidative stress and inflammatory response in microglia of the spinal cord in spinal muscular atrophy","volume":"144","author":"Ando","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.clineuro.2024.108462_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104870","article-title":"Glial cells involvement in spinal muscular atrophy: could SMA be a neuroinflammatory disease?","volume":"140","author":"Abati","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.clineuro.2024.108462_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/biom11081109","article-title":"How inflammation pathways contribute to cell death in neuro-muscular disorders","volume":"11","author":"Salucci","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.clineuro.2024.108462_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s43856-023-00256-2","article-title":"Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients","volume":"3","author":"Nuzzo","year":"2023","journal-title":"Commun. Med (Lond. )"},{"key":"10.1016\/j.clineuro.2024.108462_bib15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s13023-021-01961-8","article-title":"Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy","volume":"16","author":"Freigang","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clineuro.2024.108462_bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/acn3.51519","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy","volume":"9","author":"D\u2032Silva","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.clineuro.2024.108462_bib17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s13023-022-02547-8","article-title":"Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study","volume":"17","author":"Pechmann","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clineuro.2024.108462_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.clineuro.2024.108462_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13023-023-02769-4","article-title":"Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience","volume":"18","author":"Lusakowska","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clineuro.2024.108462_bib20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2024.108462_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12883-023-03063-3","article-title":"Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Neurol."},{"key":"10.1016\/j.clineuro.2024.108462_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/JND-221600","article-title":"Improvements in walking distance during nusinersen treatment - a prospective 3-year SMArtCARE registry study","volume":"10","author":"Pechmann","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.clineuro.2024.108462_bib23","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000465","article-title":"Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I, first-in-human study","volume":"5","author":"Thonhoff","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clineuro.2024.108462_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26040953","article-title":"The role of the inflammasome in neurodegenerative diseases","volume":"26","author":"Piancone","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.clineuro.2024.108462_bib25","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1093\/hmg\/ddv148","article-title":"Astrocytes influence the severity of spinal muscular atrophy","volume":"24","author":"Rindt","year":"2015","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.clineuro.2024.108462_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1035406","article-title":"Biological networks and complexity in early-onset motor neuron diseases","volume":"13","author":"Butchbach","year":"2022","journal-title":"Front Neurol."},{"key":"10.1016\/j.clineuro.2024.108462_bib27","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1523\/JNEUROSCI.3472-16.2017","article-title":"Decreased motor neuron support by SMA astrocytes due to diminished MCP1 secretion","volume":"37","author":"Martin","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.clineuro.2024.108462_bib28","article-title":"An Integrative transcriptomic analysis for identifying novel target genes corresponding to severity spectrum in spinal muscular atrophy","volume":"11","author":"Yang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clineuro.2024.108462_bib29","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/glia.24183","article-title":"Targeting TNFalpha produced by astrocytes expressing amyotrophic lateral sclerosis-linked mutant fused in sarcoma prevents neurodegeneration and motor dysfunction in mice","volume":"70","author":"Jensen","year":"2022","journal-title":"Glia"},{"key":"10.1016\/j.clineuro.2024.108462_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.982760","article-title":"Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment","volume":"16","author":"Bonanno","year":"2022","journal-title":"Front Cell Neurosci."},{"key":"10.1016\/j.clineuro.2024.108462_bib31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12974-019-1601-6","article-title":"Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases","volume":"16","author":"Lepennetier","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.clineuro.2024.108462_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27103194","article-title":"Neuroinflammatory markers: key indicators in the pathology of neurodegenerative diseases","volume":"27","author":"Rauf","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.clineuro.2024.108462_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14051","article-title":"Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1-3 patients treated with nusinersen","volume":"30","author":"Simic","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.clineuro.2024.108462_bib34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.braindev.2022.09.008","article-title":"Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy","volume":"45","author":"Kobayashi","year":"2023","journal-title":"Brain Dev."},{"key":"10.1016\/j.clineuro.2024.108462_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1089\/jir.2012.0132","article-title":"Pediatric reference ranges for proinflammatory and anti-inflammatory cytokines in cerebrospinal fluid and serum by multiplexed immunoassay","volume":"33","author":"Pranzatelli","year":"2013","journal-title":"J. Interferon Cytokine Res"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724003494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724003494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T20:32:58Z","timestamp":1762288378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846724003494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":35,"alternative-id":["S0303846724003494"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108462","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokines in cerebrospinal fluid as a prognostic predictor after treatment of nusinersen in SMA patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108462"}}